Single Source Procurement: MiSeqDx System Instrumentation
Pursuant to New York State Finance Law § 163.10(b), The New York State Department of Health is presenting the following summary of relevant circumstances, and material and substantial reasons why a competitive procurement was not feasible. The Illumina MiSeqDx Next-Generation Sequencing (NGS) platform and application is the only FDA approved NGS system for in-vitro use within a clinical laboratory.
| Procurement / Program Name | MiSeqDx System Instrumentation |
|---|---|
| Contractor Name(s) | Illumina, Inc. |
| Contract Period | One Time Purchase |
| Contract Numbers | OP033560 |
